Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma

Abstract

BackgroundPeripheral T-cell lymphoma (PTCL) is featured with a poor survival outcome. China has approved chidamide, an oral novel histone deacetylase inhibitor, for patients diagnosed with relapsed or refractory PTCL.ObjectiveWe compared the benefit of traditional chemotherapy alone and a combination of chidamide and traditional chemotherapy against newly diagnosed PTCL. Prognostic factors related to progression and survival in patients diagnosed with untreated PTCL were also investigated.Methods104 patients with newly diagnosed PTCL were enrolled and divided into chemotherapy (ChT) group and chemotherapy combined with chidamide (ChT+C) group. Survival curves were plotted by the Kaplan-Meier method. Univariate and multivariate analysis were conducted with Log-rank test and Cox’s proportional hazard regression. Subgroup analysis and interaction tests were conducted to evaluate factors associated with prognostic differences between ChT and ChT+C groups.ResultsCompared with patients in ChT group, those in ChT+C group had superior progression-free survival (PFS) (p=0.047). However, there was no significantly statistical difference observed between the two groups in overall survival (OS) (p=0.212). High IPI scores have a negative relationship with survival. Multivariate analysis revealed that the type of frontline treatment regimen is an independent factor associated with PFS of PTCL patients (p=0.045). In the subgroup of patients with high international prognostic index scores (3-5), the HR value for PFS comparing ChT with ChT+C was 4.675. A test of interaction between IPI and treatment showed statistical significance (p = 0.037), implying that the benefits of ChT+C are higher for patients with high IPI scores.ConclusionsIn summary, the combination of ChT and chidamide may provide a promising prospect for patients with newly diagnosed PTCL.

Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study

“…No significant increase in grade ≥ 3 adverse events or the incidence of EBV/HBV reactivation was observed. Since the IPI was found to have prognostic significance in the survival of the patients with newly diagnosed PTCL, and the choice of chemotherapy regimen may make a difference to the survival outcome, a possible explanation for the non-significantly different survival outcome may be attributed to the less benefit of C-CHOEP in patients with low IPI, which was consistent with other studies conducted in Chinese patients [25,26].…”

The efficacy and safety of a Histone deacetylase inhibitor: chidamide as a maintenance therapy for peripheral T-cell lymphoma

“…Qingqing Cai et al compared the e cacy and safety of chemotherapy combined with chidamide (ChT + C) versus chemotherapy (ChT) in newly diagnosed PTCLs, they found that patients in ChT + C group had superior PFS compared with patients in ChT group, and the bene ts of ChT + C are higher for patients with high IPI scores, there was no signi cantly statistical difference observed between the two groups in OS. It is worth noting that, the median duration of response in ChT group and ChT + C group were 10.0 months and 14.0 months, with no signi cant difference (P = 0.135) [23].…”

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, China

“…Rh-endostatin 8.2 [34] 1.83 1.02 0.39 0.22 Erlotinib 9.7 [35] 2.37 0.3 0.5 0.07 Everolimus 4.9 [36] 1.29 0.48 0.27 0.11 Chidamide 8.5 [37] 2.78 1.77 0.59 0.39 Apatinib 12 [38] 5.49 2.1 1.16 0.46 Nimotuzumab 7.29 [39] 3.51 1.06 0.74 0.23 Sunitinib 5.6 [40] 2.77 0.66 0.59 0.14 Dasatinib 4 [41] 2.06 0.38 0.44 0.08 Nilotinib 12 [42] 7.65 1.73 1.62 0.38 Sorafenib 12 [43] 7.97 1.3 1.69 0.28 Bevacizumab 11.2 [44] 8.25 1.7 1.75 0.37 Bortezomib 12 [45] 12…”